| Name | Title | Contact Details |
|---|
"Gentiva Health Services (NASDAQ: GTIV), formerly based in Melville, Long Island, New York and now in Atlanta, Georgia, is the largest provider of home health care, hospice and related services in the United States. Gentiva is a Fortune 1000 company with $1.7 billion in annual revenue. Gentiva is also a member of the S&P 600 index, developed by Standard and Poor's, featuring small capitalization U.S.-based stocks. The company offers a range of services, including nursing, physical, occupational, and speech-language therapy, cardiac and pulmonary care, disease and pain management, and other health and medical services. Gentiva provides health services to over half a million patients annuallythrough over 380 U.S. locations in 39 states. According to Morningstar, "Gentiva is a gentle giant...the nation's largest home health care services firm." Gentiva companies include Donelson, Emerald Coast, Gilbert's, Healthfield Group, Heritage, Horizon, Hospice of Charleston, Lazarus House, Tar Heel, Total Care and Wiregrass."
Battle Creek Health System (BCHS) is a multi-campus health care provider serving approximately 200,000 people in south central Michigan. BCHS was formed through the merger of Battle Creek's two acute care hospitals-Leila Y. Post Montgomery Hospital and
Legacy is America`s largest at-home fertility clinic for people with sperm, empowering individuals to learn more about their sperm and proactively plan for their future with secure sperm freezing options. Partnering with leading health plans, fertility benefits providers, US military programs, and financing merchants, Legacy is making industry-leading sperm testing and freezing affordable and accessible.
Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.
Polyzen develops and manufactures disposable medical products and devices for medical industry original equipment manufacturers.